Dennis J. Slamon

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers

R. Finn, D. Slamon, Richard S. Finn, 2016, Breast Cancer Research.

FOXA1 Represses the Molecular Phenotype of Basal Breast Cancer Cells

Gurkan Bebek, Fadi W. Abdul-Karim, Andrew K. Godwin, 2012, Oncogene.

Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial

T. Fleming, L. Norton, J. Baselga, 1998 .